Atezolizumab
Gastrointestinal Neuroendocrine Tumors
Arbele Pty Ltdmonoclonal_antibodyPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Gastrointestinal Neuroendocrine Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cabotamig Arbele Pty Ltd | Phase 1 | CC |
Oxodotreotide National Cancer Institute (NCI) | Phase 1 | CC |
[212pb]vmt-alpha-net National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Atezolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →